Precipio, Inc. (PRPO) News
Filter PRPO News Items
PRPO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest PRPO News From Around the Web
Below are the latest news stories about PRECIPIO INC that investors may wish to consider to help them evaluate PRPO as an investment opportunity.
Two Smaller Companies Worthy of Your "Attention"Here we highlight a small cap and a microcap with Zacks Outperform ratings. |
Precipio Inc (PRPO) Q3 2024 Earnings Call Highlights: Strong Growth in Diagnostic Services and ...Precipio Inc (PRPO) reports significant milestones with increased revenues and reduced cash burn, while addressing challenges in product division profitability and investor education. |
Precipio Third Quarter 2024 Earnings: US$0.42 loss per share (vs US$1.04 loss in 3Q 2023)Precipio ( NASDAQ:PRPO ) Third Quarter 2024 Results Key Financial Results Revenue: US$5.21m (up 15% from 3Q 2023). Net... |
Precipio Announces Q3-2024 Shareholder Update CallConference Call to be held on November 18, 2024, at 5:00 PM EST NEW HAVEN, Conn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2024 corporate update call on November 18th at 5:00 PM ET. The call will provide commentary on Precipio's Q3-2024 10-Q filed today, including financial highlights and analysis of the company's core businesses. The conference call may be accessed by calling 844-695-5519 (international callers |
Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation SubtypingThe unique assay enables laboratories to provide clinicians with more informed treatment decisions for their patientsNEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the launch of a new version of its Bloodhound MPN (Myeloproliferative Neoplasm) panel that is now able to distinguish between CALR type 1 and type 2 mutations. The CALR mutation data plays a critical role in disease prognosis and therapeutic decision-mak |
Precipio Announces Employee Stock Option Plan RepricingManagement lays out rationale and impact to shareholders belowNEW HAVEN, Conn., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the Company’s repricing of a portion of its employee stock options to ensure their effectiveness as a retention tool for valuable employees. Management is confident that the practical, strategic, and economic benefit to shareholders will ultimately be positive. Retaining valuable employees in an extremely c |
Zacks Initiates Coverage of Precipio With Outperform RecommendationDiscover why Zacks rates Precipio as "Outperform", being the first on Wall Street to initiate coverage on the stock. Explore PRPO's approaching breakeven milestones, financial health, and market positioning in the cancer diagnostics space. |
Precipio Announces Q2-2024 Shareholder Update CallConference Call to be held on August 19, 2024 at 5:00 PM EDTNEW HAVEN, Conn., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2024 corporate update call on August 19th at 5:00 PM ET. The call will include updates on the company’s current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. P |
Precipio Reports $0.3M cash generated by operations (unaudited) in Q2-2024, as the company advances towards breakevenCompany’s continued growth and improved cash position alleviates the need for capital raise in the foreseeable futureNEW HAVEN, Conn., July 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that its unaudited non-GAAP Cash Burn/Generated from Operations (CBFO) for Q2-2024 was $0.3M of cash generated for the quarter. It is important to note that a small contributing factor to the cash increase was the incoming cash collections that were exp |
Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024Pathology Revenues in June exceed breakeven target and continue growth trendNEW HAVEN, Conn., July 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that for Q2-2024, its unaudited revenues have grown from $3.4M in Q1-2024 to $4.4M in Q2-2024, an increase of 30% from one quarter ago. Pathology Division revenue in June reached its breakeven point, and the company anticipates continued growth in the next few months. We expect this division’s |